Syntax Bio Programs Stem Cells in Four Days

The Chicago biotech firm uses its Cellgorithm platform to create pancreatic beta cells rapidly.

Updated on Oct. 28, 2026 in Biotech

Isometric editorial illustration of clustered, spherical cellular forms arranged on a grid, representing rapid stem cell conversion technology. — Chicago-based Syntax Bio has introduced a CRISPR-based process to convert stem cells into pancreatic beta cells in four days, potentially accelerating Type 1 diabetes research. AI Illustration. Upload story photo >

Live Poll

Is it worth accelerating medical research timelines if it increases the potential for rapid therapeutic breakthroughs?

Chicago-based Syntax Bio has developed a new process that converts stem cells into pancreatic beta cells in just four days. The technology utilizes CRISPR activation to turn on specific genes without modifying the cell genome.

Why it matters

This breakthrough aims to significantly improve the speed, cost-effectiveness, and scalability of cell therapy development compared to traditional methods that take months. The process is specifically designed to support the creation of new therapies for Type 1 diabetes.

The Cellgorithm platform employs CRISPR activation technology and conditional guide RNA to trigger sequential gene expression. Researchers track the conversion process using single-cell RNA sequencing and protein expression analyses.

The players

Syntax Bio

A Chicago-based biotechnology company that spun out of the University of Illinois Chicago and focuses on stem cell programming.

International Society for Stem Cell Research

A global professional organization that hosts scientific symposia to share advancements in stem cell science and regenerative medicine.

The details

The technology avoids traditional genome editing by switching on cell genes rather than cutting the DNA. Syntax Bio presented this rapid conversion process at the International Society for Stem Cell Research symposium in Japan.

Syntax Bio emerged from stealth in 2021.
The company secured $14.4 million in series A funding in June 2026.
The technology was showcased at a symposium in October 2026.

The Tech Race

This development represents a shift from labor-intensive, multi-month cell differentiation toward faster, scalable synthetic biology approaches. It positions Syntax Bio to compete with firms seeking to accelerate the delivery of cell-based medical treatments.

The potential scalability of this technology could lead to more affordable and accessible diabetes treatments in the coming years. By shortening the production cycle, the process aims to reduce the high manufacturing costs currently associated with advanced cell therapies.

The takeaway

This breakthrough highlights how non-editing CRISPR technologies are creating new possibilities for rapid medical manufacturing. Scaling these processes effectively will be critical to moving promising laboratory research into successful clinical treatments.